Answers are grounded in this paper and cite their sources.
BACKGROUND: Neutralising monoclonal antibodies prevent and treat COVID-19 if administered early after infection with sensitive SARS-CoV-2 variants. Despite containing high neutralising antibodies, hyperimmune intravenous immunoglobulin (hIVIG) generally fails to mitigate severe COVID-19. We probed potential reasons for this discrepancy in a recent large, randomised trial (NCT04546581). METHODS: Multiplex bead arrays were used to measure SARS-CoV-2 specific FcγR binding and neutralising activity in pre-treatment sera from 481 subjects (231 placebo vs. 250 hIVIG). Associations between pre-therapy antibody FcγR engagement and day 7 clinical outcome were evaluated. RESULTS: Elevated levels of FcγRIIIa engagement by baseline spike (S)-specific antibody were associated with better clinical outcomes in COVID-19 hospitalised patients across both hIVIG- and placebo-treated groups (OR=0.43, 95%CI 0.30-0.63). Higher nucleocapsid (N) antibody-mediated FcγR engagement and surrogate neutralisation in pre-treatment sera were also modestly associated with improved outcomes. Higher pre-therapy S-specific FcγR binding antibody was also associated with reduced SARS-CoV-2 viral loads. CONCLUSIONS: Higher pre-therapy S-specific FcγR binding antibody, but not additional FcγR binding antibody provided by hIVIG, was associated with improved outcomes in severe COVID-19. Pre-existing FcγR engaging antibody, along with rapid production of these antibodies in placebo-treated subjects, may dilute potential benefits from hIVIG therapy. This work helps guide development of more strategic, targeted treatment of severe SARS-CoV-2 infection with antibody-based therapeutics.
No takes yet. Share an insight, caveat, or question.
Kent et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: